|
CN111278840A
|
|
Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer
|
|
CN111163839A
|
|
Benzimidazolone-derived BCL6 inhibitors
|
|
GB201713319D0
|
|
Compounds
|
|
GB201713318D0
|
|
Compounds
|
|
GB201708502D0
|
|
Inhibitor compounds
|
|
GB201708507D0
|
|
Inhibitor compounds
|
|
GB201708510D0
|
|
Inhibitor compounds
|
|
GB201706472D0
|
|
Tumour-targeting peptide variants
|
|
CN109195972A
|
|
Heterocyclic compound as RET kinase inhibitor
|
|
GB201705968D0
|
|
Inhibitor compounds
|
|
GB201705971D0
|
|
Inhibitor compounds
|
|
GB201702847D0
|
|
Cell labelling, tracking and retrieval
|
|
GB201615481D0
|
|
Materials and methods for prognosis of bladder cancer
|
|
WO2017029148A1
|
|
Insulin-like growth factor 2 (igf2) binding agents
|
|
HK1100368A1
|
|
Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds [45-b]-2-[45-b]-2-
|
|
SA2438B1
|
|
purine and deazapurine compounds having kinase inhibiting activity
|
